Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04545047 · ClinicalTrials.gov registry record
Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19
A clinical trial, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- 5,044
- Enrollment target
NCT04545047: Completed study, sponsored by VA Office of Research and Development.
NCT04545047 is a clinical trial that has completed, run by VA Office of Research and Development. The registered enrollment target is 5,044 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04545047 has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- 5,044 participants
- Enrollment target
Study Summary
The purpose of this study is to assess whether convalescent plasma therapy is associated with reduced 30-day all-cause mortality in a population of Veteran inpatients with non-severe coronavirus disease 2019 (COVID-19).
Primary Outcome
Death at 30 days recorded in the electronic health record. Follow-up starts at the treatment date, which must be within 2 days after both hospitalization and SARS-CoV-2-positive test, and ends at 30 days or death.
Interventions
- BIOLOGICAL COVID-19 convalescent plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,044 participants |
| Start Date | 2020-05-01 |
| Est. Completion | 2021-10-01 |
What the finished NCT04545047 record still lists
NCT04545047 is an observational study that tracks outcomes without assigning an intervention. Its 5,044 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which COVID-19 convalescent plasma is the first listed.
NCT04545047 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04545047 about?
NCT04545047 is a clinical study titled "Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19". The purpose of this study is to assess whether convalescent plasma therapy is associated with reduced 30-day all-cause mortality in a population of Veteran inpatients with non-severe coronavirus disease 2019 (COVID-19).
What is the current status of trial NCT04545047?
This trial is currently completed. The enrollment target is 5,044 participants. The study started on 2020-05-01. Estimated completion is 2021-10-01.
What interventions are being tested in trial NCT04545047?
The interventions under investigation include: COVID-19 convalescent plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT04545047?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07037459 · 5,056 participants · Phase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- NCT06292078 · 5,076 participants · NA
Preventing School Exclusion and Opioid Misuse: Effectiveness of the Inclusive Skill-building Learning Approach (ISLA)
- NCT04743362 · 5,010 participants
A Study of Noninvasive Methods to Evaluate Skin and Mucosal Conditions
- NCT00060541 · 5,000 participants
Evaluation and Treatment of Neurosurgical Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI